Product Name :
TAE-1
Description:
IC50: 0.3 ± 0.02 μM for AChE; 3.9 ± 0.2 μM for BuChE TAE-1 is an inhibitor of amyloid-β fibril formation and aggregation. Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is characterized by the cerebral accumulation of insoluble aggregates of amyloid-β peptides (Aβ). Although the precise mechanisms governing neuronal loss remains ambiguous, toxicity resulting from Aβ-activated pathways is evident. In vitro: In a previous study, the authors examined the effects of TAE-1 on differentiated human SH-SY5Y neuronal cells grown in tissue culture. Results showed that the stimulation of neuronal cellular process length and branching was noted. Moreover, the increased synaptophysin suggested that TAE-1 could stimulate synapse formation. Increased expression of MAP2 was also observed, indicating that TAE-1 promoted the differentiation of human neurons. In addition, targeted AChE inhibition was evaluated by electrochemical quantification of the enzymatic product, thiocholine, on unmodified gold screen-printed electrodes. It was found that at increasing TAE-1concentrations, there was a corresponding decrease in the AChE activity resulting in reduced amount of oxidizable thiocholine. The IC50 value was found to be 0.465 μM for TAE-1 . In vivo: Up to now, there is no animla in vivo data reported. Clinical trial: So far, no clinical study has been conducted.
CAS:
1414469-59-2
Molecular Weight:
1128.57
Formula:
C39H51I3N6O9
Chemical Name:
[2-(4-{[4,6-bis(4-{[2-(trimethylazaniumyl)ethoxy]carbonyl}phenoxy)-1,3,5-triazin-2-yl]oxy}benzoyloxy)ethyl]trimethylazanium triiodide
Smiles :
[I-].[I-].[I-].C[N+](C)(C)CCOC(=O)C1C=CC(=CC=1)OC1N=C(N=C(N=1)OC1C=CC(=CC=1)C(=O)OCC[N+](C)(C)C)OC1C=CC(=CC=1)C(=O)OCC[N+](C)(C)C
InChiKey:
SGOMELGTKOLYEZ-UHFFFAOYSA-K
InChi :
InChI=1S/C39H51N6O9.3HI/c1-43(2,3)22-25-49-34(46)28-10-16-31(17-11-28)52-37-40-38(53-32-18-12-29(13-19-32)35(47)50-26-23-44(4,5)6)42-39(41-37)54-33-20-14-30(15-21-33)36(48)51-27-24-45(7,8)9;;;/h10-21H,22-27H2,1-9H3;3*1H/q+3;;;/p-3
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
IC50: 0.3 ± 0.02 μM for AChE; 3.9 ± 0.2 μM for BuChE TAE-1 is an inhibitor of amyloid-β fibril formation and aggregation. Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is characterized by the cerebral accumulation of insoluble aggregates of amyloid-β peptides (Aβ). Although the precise mechanisms governing neuronal loss remains ambiguous, toxicity resulting from Aβ-activated pathways is evident. In vitro: In a previous study, the authors examined the effects of TAE-1 on differentiated human SH-SY5Y neuronal cells grown in tissue culture. Results showed that the stimulation of neuronal cellular process length and branching was noted.{{Proteinase K} web|{Proteinase K} Ser/Thr Protease|{Proteinase K} Technical Information|{Proteinase K} In Vitro|{Proteinase K} supplier|{Proteinase K} Cancer} Moreover, the increased synaptophysin suggested that TAE-1 could stimulate synapse formation.{{Fosamprenavir} medchemexpress|{Fosamprenavir} HIV|{Fosamprenavir} Purity & Documentation|{Fosamprenavir} In Vivo|{Fosamprenavir} supplier|{Fosamprenavir} Epigenetic Reader Domain} Increased expression of MAP2 was also observed, indicating that TAE-1 promoted the differentiation of human neurons. In addition, targeted AChE inhibition was evaluated by electrochemical quantification of the enzymatic product, thiocholine, on unmodified gold screen-printed electrodes.PMID:23892407 It was found that at increasing TAE-1concentrations, there was a corresponding decrease in the AChE activity resulting in reduced amount of oxidizable thiocholine. The IC50 value was found to be 0.465 μM for TAE-1 . In vivo: Up to now, there is no animla in vivo data reported. Clinical trial: So far, no clinical study has been conducted.|Product information|CAS Number: 1414469-59-2|Molecular Weight: 1128.57|Formula: C39H51I3N6O9|Chemical Name: [2-(4-{[4,6-bis(4-{[2-(trimethylazaniumyl)ethoxy]carbonyl}phenoxy)-1,3,5-triazin-2-yl]oxy}benzoyloxy)ethyl]trimethylazanium triiodide|Smiles: [I-].[I-].[I-].C[N+](C)(C)CCOC(=O)C1C=CC(=CC=1)OC1N=C(N=C(N=1)OC1C=CC(=CC=1)C(=O)OCC[N+](C)(C)C)OC1C=CC(=CC=1)C(=O)OCC[N+](C)(C)C|InChiKey: SGOMELGTKOLYEZ-UHFFFAOYSA-K|InChi: InChI=1S/C39H51N6O9.3HI/c1-43(2,3)22-25-49-34(46)28-10-16-31(17-11-28)52-37-40-38(53-32-18-12-29(13-19-32)35(47)50-26-23-44(4,5)6)42-39(41-37)54-33-20-14-30(15-21-33)36(48)51-27-24-45(7,8)9;;;/h10-21H,22-27H2,1-9H3;3*1H/q+3;;;/p-3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|
